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Introduction: Fibromyalgia is characterized by widespread pain and is often accompanied by accessory symptoms.
There are limited treatment options for this condition in Japan. Therefore, we conducted a phase III study to assess
the efficacy and safety of duloxetine in Japanese patients with fibromyalgia.
Methods: This randomized, double-blind, placebo-controlled, parallel-group trial was conducted in Japan. Outpatients
who met the American College of Rheumatology 1990 criteria for fibromyalgia and whose Brief Pain Inventory (BPI)
average pain score was ≥4 were randomized to duloxetine 60 mg or placebo once daily for 14 weeks. The primary
efficacy measure was the change in the BPI average pain score from baseline. Secondary efficacy, quality of life (QoL),
and safety outcomes were also evaluated. Mixed-effects model repeated-measures (MMRM) analysis and last
observation carried forward (LOCF) analysis of covariance were used to evaluate the primary efficacy measure.
Results: Overall, 393 patients were randomized to receive either duloxetine (n = 196) or placebo (n = 197). The MMRM
analysis revealed no significant difference between duloxetine and placebo regarding the change in BPI average pain
scores at week 14. Based on LOCF analysis, a statistically significant improvement in the change in BPI average pain scores
at week 14 was observed for patients treated with duloxetine compared with placebo. Duloxetine treatment was
associated with improved outcomes in nearly all secondary and post hoc analyses. The treatment was generally well
tolerated. Somnolence, nausea, and constipation were the most common treatment-emergent adverse events in the
duloxetine group. The discontinuation rates due to treatment-emergent adverse events were similar in both groups.
Conclusions: Although the MMRM analysis did not demonstrate superiority of duloxetine over placebo, duloxetine
treatment was associated with improved outcomes in secondary and post hoc analyses of the mean change in the BPI
average pain score and most of the secondary outcomes, including analgesia and QoL. Duloxetine treatment was safe
and well tolerated. These results suggest that duloxetine treatment could be associated with improvements in pain relief
and QoL in Japanese patients with fibromyalgia.
Trial registration: ClinicalTrials.gov Identifier: NCT01552057. Registered 9 March 2012.Introduction
Fibromyalgia is a disorder characterized by widespread
pain. In addition to widespread pain, patients with fibro-
myalgia frequently experience other troublesome symp-
toms, such as fatigue, sleep disturbances, and cognitive
disturbances; other specific painful conditions such as
chronic headache, temporomandibular disorders, and
irritable bowel syndrome; and psychiatric comorbid* Correspondence: kusuki-nishioka@bz04.plala.or.jp
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more, fibromyalgia often has negative effects on personal
relationships, careers, and daily activities [1–7]. Accord-
ing to the 1990 American College of Rheumatology
(ACR) criteria for the classification of fibromyalgia [2],
the diagnosis consists of two components: presence of
widespread pain for at least 3 months and presence of
tenderness at 11 or more of the 18 specific tender point
sites. The presence of associated symptoms was included
as a required component of fibromyalgia diagnosis in
the preliminary diagnostic criteria for fibromyalgiarticle is distributed under the terms of the Creative Commons Attribution
mons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
you give appropriate credit to the original author(s) and the source,
ense, and indicate if changes were made. The Creative Commons Public
ommons.org/publicdomain/zero/1.0/) applies to the data made available in
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2011 [9].
In an epidemiological survey conducted in 2004, the
Ministry of Health, Labour and Welfare of Japan re-
ported a prevalence of fibromyalgia in Japan of 1.7 %, ac-
counting for approximately 2 million individuals [1, 10],
which is similar to the prevalence (2.0 %) reported in a
U.S. study [3]. This prevalence rate in Japan is consistent
with the results of an internet survey conducted in 2011
[6]. The male-to-female ratio of affected individuals was
1:4.8, and the mean (SD) age was 51.5 (16.9) years. Thus,
in Japan, fibromyalgia predominantly affects middle-
aged and elderly women. However, there are few clini-
cians in Japan who are aware of this disease and are able
to diagnose it correctly. Reportedly, it can take approxi-
mately 4 years to establish a definitive diagnosis of fibro-
myalgia in Japan [1, 10]. In the same survey, patients
reported dissatisfaction with current treatment.
Three agents (duloxetine, milnacipran, and pregabalin)
have been approved for treatment of fibromyalgia in the
United States [11]. Conversely, in Japan, the Diagnostic
Guidelines for Fibromyalgia 2013 document [1] lists a
wide variety of agents for treatment, including antide-
pressants (tricyclic antidepressants, serotonin (5-HT)
and noradrenaline (NA) reuptake inhibitors, and selective
5-HT reuptake inhibitors), anticonvulsants, and Neurotro-
pin (an extract obtained from cutaneous tissue of rabbits
inoculated with vaccinia virus; Nippon Zoki Pharmaceut-
ical Co., Ltd., Osaka, Japan). Currently, however, only preg-
abalin is approved for the treatment of fibromyalgia in
Japan, and the lack of other options is considered an obs-
tacle in the treatment of this condition. Both 5-HT and NA
have been thought to mediate the endogenous pain-
inhibitory mechanisms via the descending pain inhibitory
pathways in the brain and spinal cord [12, 13]. In chronic
pain states, the net inhibitory effect of these monoamines
appears to be reduced or lost, shifting the descending pain
modulatory system from a state of inhibition toward a state
of pain facilitation [14]. Duloxetine is a potent and selective
inhibitor of 5-HT and NA reuptake in vitro and in vivo in
the central nervous system (CNS). The analgesic effects of
duloxetine are believed to result from increased activity of
5-HT and NA within the CNS, presumably either by enhan-
cing the descending pain inhibitory pathways in the brain
and spinal cord or via other unknown CNS actions [15, 16].
Clinical studies conducted in other countries in patients
with fibromyalgia have demonstrated the safety and efficacy
of duloxetine compared with placebo [17–22]. Furthermore,
duloxetine has been approved for the treatment of pain as-
sociated with diabetic peripheral neuropathic pain, chronic
pain caused by osteoarthritis, and chronic low back pain.
In Japan, duloxetine has been approved for treatment
of major depressive disorder and diabetic peripheral
neuropathic pain after its efficacy for these conditionswas validated in phase III studies [23, 24]. Despite the
lack of clinical study evidence of the efficacy of duloxe-
tine among Japanese patients with fibromyalgia, there is
a strong demand from the Japan College of Fibromyalgia
Investigation and the Ministry of Health, Labour and
Welfare to develop an indication for using duloxetine to
treat fibromyalgia. Therefore, we conducted a phase III
study to formally assess the efficacy and safety of du-
loxetine at 60 mg once daily compared with placebo in
Japanese patients with fibromyalgia.
Methods
Overview
This randomized, multicenter, double-blind, placebo-
controlled, parallel-group, phase III trial was conducted
in 42 outpatient clinics and hospitals (listed in the
Acknowledgments) in Japan between March 2012 and
December 2013. An institutional review board for each
site (listed in the Appendix) approved the protocol, and
all patients provided written informed consent before
study commencement. The study was conducted in compli-
ance with the International Conference on Harmonisation
Good Clinical Practice guidelines. All monitoring activities
for this study were outsourced to SRL Medisearch, Inc.,
Tokyo, Japan. This study was registered at ClinicalTrials.gov
under the identifier NCT01552057 on 9 March 2012.
There were no changes to the methods or planned
endpoints after study initiation.
Eligibility criteria
The criteria used in a previous study of duloxetine [25]
were adopted. Briefly, male and female outpatients aged
between 20 and 75 years who met the ACR 1990 criteria
for fibromyalgia [2] and had a Brief Pain Inventory (BPI)
average pain score ≥4 [26, 27] at visits 1 and 2 were
included. Exclusion criteria were as follows: past duloxe-
tine treatment; serious or medically unstable disease,
clinically significant abnormal laboratory values, or ab-
normal electrocardiogram (ECG) findings; pain caused
by non-fibromyalgia diseases; poorly controlled thyroid
dysfunction; rheumatoid, inflammatory, or infectious
arthritis; autoimmune disorders other than thyroid dys-
function; psychiatric disorders other than major de-
pressive disorder within the past year; and suicidal
tendencies as assessed using the Columbia-Suicide
Severity Rating Scale (C-SSRS) [28].
Patients were prohibited from using analgesics and
drugs with analgesic effects, including nonsteroidal anti-
inflammatory drugs, anticonvulsants, pregabalin, neuro-
tropin, anesthetics, opioids, and adrenocorticosteroids.
The use of analgesics for up to 3 consecutive days and
for up to a total of 10 days was permitted only for the
treatment of adverse events (AEs). Coadministration of
acetaminophen at doses up to 1500 mg/day was permitted
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cept on the day before efficacy was evaluated after visit 2
and until just before the evaluation. The use of prophylac-
tic aspirin at doses up to 325 mg/day to prevent cardiac
events was also permitted. Patients taking mood-affecting
drugs such as antidepressants, sedatives, and benzodiaze-
pines were also excluded. Zopiclone and zolpidem were
the only hypnotics permitted during the study, as long as
their use began before the participant entered the screen-
ing phase (i.e., before visit 1), without dosing changes.
Tender point injections and nerve blocks were to be
stopped before visit 1. Non-drug therapies (e.g., exercise
therapy and cognitive behavioral therapy) received at least
14 days before visit 1 were permitted during the study, as
long as no changes were made.
Study design
This randomized, multicenter, double-blind, placebo-
controlled, parallel-group phase III trial consisted of
four phases. The study lasted 17–18 weeks and included
a 1- to 2-week screening phase, a 14-week treatment
phase, a 1-week dose-tapering phase, and a 1-week follow-
up observation phase (Fig. 1). After the screening phase,
patients were assigned randomly to receive duloxetine or
placebo in a 1:1 ratio, using a web-based patient regis-
tration system (ACRONET Corp., Tokyo, Japan) with a
stochastic minimization procedure. The following alloca-
tion factors were used: (1) BPI average pain score at visit 2
(<6 vs. ≥6) and (2) presence or absence of concomitant
major depressive disorder diagnosed on the basis of
the M.I.N.I. International Neuropsychiatric Interview–
Japanese version 5.0.0 [29]. It was ensured that the maxi-
mum between-group difference in the number of subjects
in each medical institution did not exceed two. Blinding
was maintained until the end of the study by the person
responsible for the study drug assignment.
Duloxetine or placebo was orally administered once
daily after breakfast on a double-blind basis. In the
duloxetine group, patients received 20 mg for 1 week,Fig. 1 Study designfollowed by 40 mg for 1 week and then 60 mg for
12 weeks during the treatment phase. In the placebo
group, subjects received placebo for 14 weeks through-
out the treatment phase. Down-titration was performed
after completion of the treatment phase or if the patient
discontinued after at least 2 weeks of treatment with
duloxetine (i.e., if the patient was taking 40 or 60 mg at
the time of discontinuation). The drug allocation con-
troller confirmed the study drugs were undiscernible in
terms of appearance, packaging, and labeling, and mock
titration of placebo pills was also performed to maintain
blinding. Only the drug allocation controller was aware
of the type of drugs being dispensed.Outcome measures
Primary efficacy outcomes
The primary efficacy measure was the change in the BPI
average pain score from baseline (visit 2) to the end of
the 14-week treatment phase (visit 7). The pain score
was based on a scale from 0 (no pain) to 10 (pain as bad
as patient can imagine).Secondary efficacy outcomes
Secondary outcomes included the “worst pain severity,”
“least pain severity,” and “pain right now” items of the
BPI; pain interference with seven daily activities (general
activity, walking, work, mood, enjoyment of life, rela-
tionships with others, and sleep); data reported in patient
diaries; and scores on the Patient Global Impression of
Improvement (PGI-I) and the Clinical Global Impressions–
Global Improvement (CGI-I) [30]. Pain interference was
assessed on a 0 (does not interfere) to 10 (completely
interferes) rating scale. Items corresponding to the average
and worst pain severity items of the BPI were recorded
daily by each patient in the patient diary. The average
weekly values were calculated based on the diary. PGI-I
and CGI-I [30] were assessed separately by the subjects
and physicians on a scale ranging from 1 (very much
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improvement from baseline.
Health outcomes
Patients responded to the Fibromyalgia Impact Question-
naire (FIQ; Japanese version) [31, 32], consisting of 20
questions about the symptoms and discomforts of fibro-
myalgia. Responses were summed to yield a total score
ranging from 0 (no impact) to 100 (maximum impact).
Using the 36-Item Short-Form Survey (SF-36; Japanese
version 2) [33, 34], patients assessed their health status
by answering 36 questions measuring the following eight
subscales, rated 0–100 (with higher scores indicating
better health status): physical functioning, physical role
functioning, emotional role functioning, general health
perceptions, social role functioning, bodily pain, vitality,
and mental health.
Using the Beck Depression Inventory II (BDI-II) [35, 36],
patients assessed 21 items related to symptoms of depres-
sion on a 4-point (0–3) scale. Responses were summed to
yield a total score that ranged from 0 to 63 (with higher
scores indicating more severe depressive symptoms). The
widespread pain index (WPI) and symptom severity (SS)
scale of the ACR 2010 criteria [8, 37] were assessed, with
maximum scores of 19 and 12, respectively.
Safety outcomes
Safety was assessed on the basis of the presence or ab-
sence and incidence of AEs and adverse drug reactions
(ADRs) reported during the treatment phase until the
end of the follow-up observation phase. Additionally,
laboratory tests (hematology, clinical chemistry, and
urinalysis), ECG, body weight, and vital signs were mea-
sured. The presence or absence of suicidal tendencies
was assessed using the C-SSRS.
Statistical analyses
Based on clinical data from three previous studies [20–22],
the between-group difference in the change in the
BPI average pain score from baseline was estimated
to be −0.70 between the duloxetine and placebo groups,
with a standard deviation of 2.38 for the change in pain
score. Therefore, this study required a total of 370 patients
to have a power of at least 80 % at a significance level of
0.05 (two-sided). All efficacy analyses were conducted
using the full analysis set (FAS), which comprised all ran-
domized patients who received at least one dose of the al-
located study drug and had a baseline and at least one
postbaseline BPI average pain score. Safety analyses were
conducted using the safety analysis set, which was defined
as all randomized patients who were administered the
study drugs at least once. Unless otherwise noted, the
treatment effects were tested at a two-sided significance
level of 0.05.The primary efficacy measure was analyzed using a mixed-
effects model repeated-measures (MMRM) approach to
compare the change from baseline in BPI average pain score
at week 14 of study treatment between the duloxetine and
placebo groups. The model included treatment, week, and a
treatment ×week interaction as fixed effects, as well as the
baseline pain score and presence or absence of concomitant
major depressive disorder diagnosed as covariates. The
change in BPI average pain score from baseline to week 14
of treatment was also compared between the groups by ana-
lysis of covariance (ANCOVA) with the baseline value and
presence or absence of major depressive disorder as covari-
ates. The missing data at week 14 of treatment were imputed
based on the last observation carried forward (LOCF) ap-
proach. Post hoc ANCOVA was used for additional sensitiv-
ity analyses of the primary efficacy measure. In these post
hoc analyses, the baseline observation carried forward
(BOCF) or worst observation carried forward (WOCF)
values were carried forward to impute missing data instead
of the LOCF method being used. The proportions of re-
sponders were calculated for patients with a reduction in the
BPI average pain score of ≥30 % from baseline to endpoint
or ≥50 % from baseline to endpoint, and also for patients
with a sustained response. Sustained response was defined
as ≥30 % reduction from baseline to endpoint in the BPI
average pain score with a 30 % reduction from baseline at
an earlier visit (at least 2 weeks prior) and ≥20 % reduc-
tion from baseline for every visit in between if there were
any intervening visits. These proportions were compared
between the groups using a Mantel–Haenszel test ad-
justed for the allocation factors.
Unless otherwise noted, the MMRM approach was used to
evaluate the differences in the changes in other secondary
endpoints from baseline between the duloxetine and placebo
groups. PGI-I and CGI-I scores were analyzed using a
MMRM model without baseline as a covariate. In post hoc
analyses, PGI-I and CGI-I at week 14 were compared between
the treatment groups using Wilcoxon’s rank-sum test with the
LOCF approach. For SF-36, changes from baseline to week 14
of treatment were compared between the duloxetine and
placebo groups using the LOCF ANCOVA approach.
Path analysis, which consists of the following two
regression models, was performed to estimate a direct an-
algesic effect relative to an indirect effect on pain reduc-
tion through an improvement in depressive symptoms:
Y 1 ¼ α0 þ α1X1 þ α2Y 2 þ α3Z1 þ α4Z2
and
Y 2 ¼ β0 þ β1X1 þ β2Z1 þ β3Z2;
where Y1 is the change from baseline in BPI average pain
score, Y2 is the change from baseline in BDI-II total score,
X1 is treatment, Z1 is baseline BDI-II total score, and Z2 is
baseline BPI average pain score. The direct and indirect
Table 1 Patient characteristics (full analysis set)
Placebo (n = 195) Duloxetine (n = 191) p Value
Age, yr 49.5 ± 11.7 47.8 ± 12.0 0.1373a
Females 164 (84.1) 157 (82.2) 0.6837
Weight, kg 56.28 ± 10.47 58.00 ± 11.23 0.1219a
Height, cm 159.61 ± 7.76 159.41 ± 7.40 0.7922
Major depressive
disorder diagnosis
7 (3.6) 8 (4.2) 0.7980
Duration of
fibromyalgia, yr
5.7 ± 6.6 5.5 ± 5.9 0.6968
Number of tender
points
15.5 ± 2.3 15.4 ± 2.3 0.8740
BPI average pain
score (0–10)
6.13 ± 1.35 6.05 ± 1.29 0.5456
FIQ total
score (0–100)
56.82 ± 16.14 55.95 ± 16.25 0.5950
BDI-II total
score (0–63)
14.89 ± 9.62 15.34 ± 9.73 0.6533
BDI-II Beck Depression Inventory II, BPI Brief Pain Inventory, FIQ Fibromyalgia
Impact Questionnaire
Values are means ± standard deviation or n (%). Continuous variables were
analyzed using Welch’s t test, and categorical variables were analyzed using
Fisher’s exact test
aStatistically significant at a two-sided significance level of 0.15
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respectively. Then, the contribution (as a percentage) of
each effect to the total effect, which was defined as the sum
of the direct and indirect effects, was calculated if feasible.
Incidences of AEs and ADRs were compared between
the treatment groups using Fisher’s exact test. The AEs
and ADRs reported were coded with MedDRA (version
16.1; Medical Dictionary for Regulatory Activities, McLean,
VA, USA), and the incidences were tabulated for each pre-
ferred term by treatment group.
Results
Patient disposition and characteristics
In total, 393 patients were enrolled and assigned randomly
to receive placebo (n = 197) or duloxetine (n = 196). In the
placebo and duloxetine groups, 2 and 5 patients, respect-
ively, were excluded from the FAS and 149 and 166
patients, respectively, completed the study treatment.
Although more patients withdrew because of a lack of effi-
cacy in the placebo group (placebo, 23 [11.7 %]; duloxe-
tine, 8 [4.1 %]), a similar proportion of patients withdrew
from each group because of AEs (placebo, 15 [7.6 %];
duloxetine, 14 [7.1 %]) (Fig. 2). The majority of pa-
tients were women (83.2 %), with a mean ± SD age of
48.7 ± 11.9 years. Both groups were balanced in terms
of baseline demographic characteristics (Table 1).Fig. 2 Patient disposition. *Includes discontinuations due to serious adverse events, adverse events, or adverse drug reactions (some patients
discontinued because of multiple events). †These patients were included in the safety analysis. BPI Brief Pain Inventory; FAS full analysis set
Murakami et al. Arthritis Research & Therapy  (2015) 17:224 Page 6 of 13Efficacy and health outcomes
Although there was no statistically significant difference
between the duloxetine and placebo groups in the reduc-
tion of the BPI average pain score at week 14 (p = 0.0988)
in the MMRM analysis, a statistically significant improve-
ment in BPI average pain scores at week 14 was observed
for patients treated with duloxetine compared with pla-
cebo when we used the LOCF ANCOVA approach
(Table 2, Fig. 3). The post hoc BOCF and WOCF analyses
also showed that the change in average pain score
was significantly greater in the duloxetine group (both
p = 0.0132) than in the placebo group (Table 2). Ana-
lyses of the proportion of responders with pain reduc-
tion ≥30 % (p = 0.0130) or ≥50 % (p = 0.0318) and the
sustained response rate (p = 0.0139) in the BPI average
pain score indicated that the reduction in pain was signifi-
cantly greater in the duloxetine group than in the placebo
group (Fig. 4).
Regarding the secondary outcome measures of pain,
duloxetine treatment was associated with significant
reductions in BPI worst pain, BPI least pain, BPI pain
right now, worst pain in patient diary, FIQ pain score,
and SF-36 bodily pain score (Table 2). General illness,
measured using the CGI-I and PGI-I, was also significantly
improved in the duloxetine group in terms of both the
mean scores (Table 2) and the proportions of clinicians
and patients reporting improvements in CGI-I and PGI-I
(Fig. 5). Duloxetine treatment was also associated with a
significant improvement in the patients’ quality of life
(QoL) as measured by the patient-related health outcomes
BPI interference, FIQ score, and SF-36 score (Table 2). A
significant improvement with a between-group difference
of −1.64 (95 % CI, −2.74, −0.54; p = 0.0037) was also ob-
served in the total WPI and SS scores (Table 2). The pro-
portion of patients matching ACR 2010 criteria (WPI ≥7
and SS ≥5 or WPI 3–6 and SS ≥9) in the FAS was 85.0 %.
The path analysis of BPI average pain score performed
to estimate the direct analgesic effect indicated that
treatment effect at the study endpoint did not corres-
pond to a sizable portion of the total effect (Table 3).
The direct reduction of the BPI average pain score by
duloxetine accounted for 28.3 % of the total treatment
effect, whereas the indirect treatment effect through im-
provement of depressive symptoms accounted for 71.7 %
of the total treatment effect.
Safety and tolerability
There were no deaths reported during the study. Two
serious AEs (pneumonia and asthma) were reported in
one patient in the placebo group. One serious AE (liver
injury) was reported in one patient in the duloxetine
group, and the investigator could not exclude the possi-
bility of a relationship between the AE and the study
drug. That patient recovered after discontinuation of thestudy drug. The number of patients who discontinued
treatment because of AEs was similar in both groups,
with 15 and 14 patients in the placebo and duloxetine
groups, respectively. Somnolence (placebo, 10.7 % vs.
duloxetine, 26.3 %), nausea (4.6 % vs. 21.6 %), constipa-
tion (4.1 % vs. 14.9 %), decreased appetite (0.5 % vs.
6.7 %), and dizziness (1.0 % vs. 5.7 %) were significantly
more frequent in the duloxetine group than in the pla-
cebo group (Table 4). Most of the adverse effects were
mild in severity, and patients either recovered immedi-
ately or promptly after treatment discontinuation. No
distinct changes attributable to duloxetine were observed
in laboratory test results, blood pressure and pulse rate,
body weight, or ECG. None of the patients had an ap-
parent suicide risk according to the C-SSRS.
Discussion
Analgesic effect of duloxetine on fibromyalgia
In this randomized, multicenter, double-blind, placebo-
controlled phase III trial of duloxetine in Japanese patients
with fibromyalgia, the MMRM analysis of the primary effi-
cacy measure, in which we compared the change in BPI
average pain scores from baseline to week 14 between
duloxetine and placebo groups, did not demonstrate super-
iority of duloxetine over placebo. However, when the change
in BPI average pain score at each evaluation time point was
examined, a significant improvement was observed at all the
evaluation time points (from weeks 2 to 10) in the duloxe-
tine group compared with the placebo group.
The efficacy and safety of duloxetine in the treatment of
fibromyalgia was previously investigated in four randomized,
double-blind, placebo-controlled trials in other countries [17,
20–22]. A pooled analysis of the results of these trials showed
that 12 weeks of treatment with duloxetine significantly re-
duced pain compared with placebo beginning in the first
week of treatment and that this reduction continued at each
subsequent week throughout the 12 weeks of therapy [18].
Furthermore, analysis of the change in BPI average pain
score from baseline to week 14 using ANCOVA (with
missing data imputed by LOCF) showed a significant
improvement in the duloxetine group compared with the
placebo group. These results are consistent with those of
earlier international studies [20, 21] in which researchers
evaluated once-daily duloxetine 60 mg and reported a signifi-
cant improvement in the change from baseline to study end-
point (using LOCF) in the duloxetine group compared with
the placebo group, based on ANCOVA. In these countries,
including the United States, once-daily duloxetine 60 mg
was approved for the treatment of fibromyalgia on the basis
of such clinical study data.
Moreover, in post hoc analyses of the results of our
present study, the change from baseline to week 14 in
BPI average pain scores was compared when missing
data due to discontinuations were imputed using the
Table 2 Changes in efficacy measures from baseline to endpoint or at endpoint
Variable Placebo (n = 195) Duloxetine (n = 191) Difference (95 % CI) p Value
Baseline Change Baseline Change
BPI average pain score
MMRM 6.13 ± 1.35 −1.58 ± 0.23 6.05 ± 1.29 −1.90 ± 0.23 −0.32 (−0.70, 0.06) 0.0988
LOCF 6.13 ± 1.35 −1.22 ± 0.26 6.05 ± 1.29 −1.60 ± 0.26 −0.38 (−0.74, −0.02) 0.0408a
BOCF 6.13 ± 1.35 −0.92 ± 0.25 6.05 ± 1.29 −1.38 ± 0.25 −0.45 (−0.81, −0.10) 0.0132a
WOCF 6.13 ± 1.35 −0.88 ± 0.26 6.05 ± 1.29 −1.35 ± 0.26 −0.47 (−0.84, −0.10) 0.0132a
BPI other pain
Worst 7.44 ± 1.40 −1.35 ± 0.26 7.36 ± 1.28 −1.91 ± 0.26 −0.56 (−0.99, −0.12) 0.0126a
Least 4.46 ± 1.81 −1.23 ± 0.22 4.68 ± 1.70 −1.72 ± 0.22 −0.49 (−0.87, −0.12) 0.0092a
Right now 5.90 ± 1.69 −1.20 ± 0.26 5.99 ± 1.52 −1.77 ± 0.26 −0.57 (−1.00, −0.15) 0.0083a
Patient diary
Average pain 5.98 ± 1.39 −1.48 ± 0.18 5.79 ± 1.35 −1.82 ± 0.18 −0.33 (−0.70, 0.03) 0.0755
Worst pain 7.23 ± 1.28 −1.34 ± 0.19 7.05 ± 1.24 −1.81 ± 0.19 −0.47 (−0.88, −0.06) 0.0232a
BPI interference scores
General activities 5.82 ± 2.31 −1.76 ± 0.32 5.82 ± 2.14 −2.22 ± 0.31 −0.46 (−0.98, 0.06) 0.0807
Mood 5.33 ± 2.53 −1.42 ± 0.33 5.65 ± 2.40 −2.17 ± 0.32 −0.75 (−1.29, −0.22) 0.0057a
Walking ability 4.08 ± 2.85 −1.29 ± 0.30 4.29 ± 2.73 −1.67 ± 0.29 −0.38 (−0.84, 0.09) 0.1114
Normal work 5.50 ± 2.46 −1.76 ± 0.32 5.61 ± 2.42 −2.18 ± 0.31 −0.42 (−0.94, 0.09) 0.1081
Relationships with people 3.54 ± 2.97 −0.53 ± 0.30 3.90 ± 2.89 −1.09 ± 0.30 −0.55 (−1.04, −0.07) 0.0264a
Sleep 5.22 ± 2.91 −1.57 ± 0.36 5.30 ± 2.81 −1.82 ± 0.35 −0.24 (−0.81, 0.32) 0.3959
Enjoyment of life 5.13 ± 2.75 −1.24 ± 0.32 5.12 ± 2.65 −1.90 ± 0.31 −0.66 (−1.18, −0.15) 0.0119a
Average of all 7 items 4.95 ± 2.09 −1.44 ± 0.27 5.10 ± 2.07 −1.95 ± 0.27 −0.52 (−0.96, −0.07) 0.0222a
FIQ
Physical functioning 3.85 ± 2.32 −0.37 ± 0.26 3.36 ± 2.35 −0.84 ± 0.25 −0.47 (−0.86, −0.09) 0.0160a
Feeling good 7.11 ± 2.73 −0.79 ± 0.41 7.17 ± 2.72 −1.59 ± 0.40 −0.80 (−1.39, −0.21) 0.0082a
Missing work 2.44 ± 2.79 −0.48 ± 0.28 2.33 ± 3.09 −0.97 ± 0.27 −0.49 (−0.93, −0.06) 0.0270a
Housework 5.86 ± 2.39 −1.69 ± 0.36 5.86 ± 2.45 −2.14 ± 0.35 −0.45 (−0.97, 0.08) 0.0932
Pain 7.01 ± 1.67 −1.76 ± 0.35 6.83 ± 1.52 −2.37 ± 0.34 −0.62 (−1.11, −0.12) 0.0148a
Fatigue 7.27 ± 2.08 −1.45 ± 0.35 7.08 ± 1.97 −1.96 ± 0.34 −0.52 (−1.03, 0.00) 0.0479a
Morning tiredness 6.81 ± 2.41 −1.68 ± 0.39 6.86 ± 2.40 −1.80 ± 0.37 −0.13 (−0.69, 0.44) 0.6618
Stiffness 6.26 ± 2.56 −1.59 ± 0.35 6.20 ± 2.57 −2.10 ± 0.34 −0.51 (−1.03, 0.02) 0.0577
Anxiety 5.43 ± 2.67 −1.18 ± 0.36 5.33 ± 2.59 −1.86 ± 0.35 −0.68 (−1.20, −0.15) 0.0114a
Depression 4.79 ± 2.71 −0.96 ± 0.35 4.91 ± 2.76 −1.62 ± 0.34 −0.66 (−1.18, −0.14) 0.0129a
Total score 56.82 ± 16.14 −13.05 ± 2.65 55.95 ± 16.25 −18.41 ± 2.57 −5.35 (−9.26, −1.45) 0.0073a
SF-36
Physical functioning 62.51 ± 19.82 3.04 ± 2.15 63.72 ± 18.75 7.40 ± 2.13 4.36 (1.35, 7.37) 0.0046a
Physical role limitations 49.13 ± 25.60 0.44 ± 2.98 49.25 ± 25.57 8.20 ± 2.96 7.76 (3.57, 11.94) 0.0003a
Bodily pain 36.60 ± 11.71 5.28 ± 2.08 36.53 ± 12.40 10.95 ± 2.07 5.67 (2.76, 8.59) 0.0002a
General health perceptions 38.76 ± 14.77 3.31 ± 1.94 39.37 ± 17.67 6.55 ± 1.92 3.25 (0.53, 5.96) 0.0192a
Vitality 31.96 ± 18.80 3.35 ± 2.53 32.43 ± 21.03 10.05 ± 2.51 6.70 (3.15, 10.25) 0.0002a
Social functioning 55.71 ± 26.54 3.28 ± 3.06 55.76 ± 27.53 10.32 ± 3.04 7.04 (2.74, 11.34) 0.0014a
Emotional role limitations 61.24 ± 26.80 −3.63 ± 3.36 60.34 ± 29.16 5.50 ± 3.35 9.12 (4.41, 13.83) 0.0002a
Mental health 56.10 ± 19.84 −2.00 ± 2.52 55.50 ± 18.85 5.91 ± 2.51 7.91 (4.39, 11.43) <0.0001a
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Table 2 Changes in efficacy measures from baseline to endpoint or at endpoint (Continued)
CGI-Ib – 3.27 ± 0.16 – 2.83 ± 0.15 −0.44 (−0.71, −0.18) 0.0012a
PGI-Ib – 3.32 ± 0.16 – 2.83 ± 0.16 −0.49 (−0.76, −0.22) 0.0003a
BDI-II score (0–63) 14.89 ± 9.62 −1.19 ± 0.85 15.34 ± 9.73 −4.09 ± 0.84 −2.90 (−4.37, −1.44) 0.0001a
ACR 2010
WPI (0–19) 12.08 ± 3.57 −1.06 ± 0.60 12.14 ± 3.58 −2.34 ± 0.58 −1.28 (−2.12, −0.44) 0.0029a
SS (0–12) 6.59 ± 1.88 −1.00 ± 0.28 6.60 ± 1.82 −1.37 ± 0.27 −0.36 (−0.79, 0.06) 0.0906
Total (0–31) 18.67 ± 4.53 −2.24 ± 0.77 18.74 ± 4.36 −3.88 ± 0.74 −1.64 (−2.74, −0.54) 0.0037a
ACR American College of Rheumatology, BDI-II Beck Depression Inventory II, BOCF baseline observation carried forward, BPI Brief Pain Inventory, CGI-I Clinical
Global Impressions–Global Improvement, CI confidence interval, FIQ Fibromyalgia Impact Questionnaire, LOCF last observation carried forward; MMRM mixed-effects
model repeated measures, PGI-I Patient Global Impression of Improvement, SF-36 36-Item Short Form Survey; SS symptom severity; WOCF worst observation carried
forward, WPI widespread pain index
Values are means ± SD (baseline) or least-squares means ± SE (change)
aStatistically significant at a two-sided level of 0.05
bMean scores at the end of treatment based on a 7-point scale
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with either of the missing data imputation methods, a
significant improvement was observed in the duloxetine
group compared with the placebo group. In this clinical
trial, there were more patients who discontinued the
trial because of an inadequate improvement in the BPI
average pain score or exacerbation of pain in the placebo
group (11.7 %) compared with the duloxetine group
(4.1 %). Therefore, the MMRM analysis might introduce
a bias toward greater improvement in BPI average pain
score in the placebo group than in the duloxetine group.
Of the seven pain-related items among the secondary ef-
ficacy measures, six (BPI pain scores [worst, least, and
pain right now], worst pain reported in the patient diary,Fig. 3 Changes in Brief Pain Inventory average, worst, least, and right now pa
vs. placebo. Dashed lines, placebo; black solid lines, duloxetine. LOCF last obserFIQ pain score, and SF-36 [bodily pain]) showed a signifi-
cant improvement from baseline to week 14 of treatment
in the duloxetine group compared with the placebo group.
Although the superiority of duloxetine over placebo was
not demonstrated in the MMRM analysis of the primary
efficacy measure, a significant improvement in the duloxe-
tine group compared with the placebo group was ob-
served in the secondary and post hoc analyses and several
other secondary efficacy measures. These results suggest
that treatment with duloxetine could be associated with
improvement in pain relief in Japanese patients with
fibromyalgia.
Moreover, the 30 %, 50 %, and sustained pain reduc-
tions based on the change at endpoint in the BPI averagein scores from baseline. Values are means at each time point. *p < 0.05
vation carried forward; LS least squares
Fig. 4 Response rates for the Brief Pain Inventory (BPI) average pain scores at the end of treatment. *p < 0.05 vs. placebo. Open bars, placebo;
filled bars, duloxetine
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group than in the placebo group. According to the
Initiative on Methods, Measurement, and Pain Assessment
in Clinical Trials (IMMPACT) recommendations, patients
with a clinically relevant reduction in the assessment scale
of 30–50 % compared with baseline are considered re-
sponders [38]. Therefore, the rate of responders was sig-
nificantly higher in the duloxetine group than in the
placebo group in the present trial. Considering that we
assessed patients with moderate or severe fibromyalgia,
with characteristics similar to those of the patients enrolledFig. 5 Patient Global Impression of Improvement (PGI-I) and Clinical Global Im
PGI-I and CGI-I scores were recorded on a 7-point scale where 1 = very much
4 = no change, 5 = a little worse, 6 =much worse, and 7 = very much worse. *in Japanese epidemiological studies [10], duloxetine treat-
ment might benefit such individuals.
The path analysis performed in this study suggested
that the direct effect of duloxetine on the reduction of
the BPI average pain was smaller than the indirect
treatment effect, as evidenced by the improvement in
depressive symptoms at study endpoint. The changes in
both BPI average pain score and BDI-II score indicated
improvements in these symptoms. Because the between-
groups difference at the last evaluation was large for
BDI-II and small for BPI average pain score, we estimatepressions–Global Improvement (CGI-I) ratings at the end of treatment.
better/improved, 2 =much better/improved, 3 = a little better/improved,
p < 0.05 vs. placebo
Table 3 Path analysis for direct analgesic effect on the
reduction of the BPI average pain score
Week Direct effect Indirect effect
Week 2a 84.3 15.7
Week 4a 83.8 16.2
Week 6a 63.1 36.9
Week 10a 43.2 56.8
Week 14a 41.6 58.4
Endpointb 28.3 71.7
Values are the percentages of direct and indirect effects
aObserved case
bLast observation carried forward
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direct analgesic effect) to the whole analgesic effect was
high. In the present clinical study, however, the propor-
tion of patients with a complication of major depressive
disorder was small compared with the proportions ob-
served in other studies: major depressive disorder was
diagnosed in only eight patients (4.2 %) in the duloxetine
group and seven patients (3.6 %) in the placebo group in
our study. Thus, an evaluation of exactly how much of
the analgesic effect of duloxetine was due to its anti-
depressant effect was considered difficult. A subgroupTable 4 Adverse events (safety analysis set)
Placebo (n = 196) Duloxetine (n = 194) p Valuea
AEs 123 (62.8) 148 (76.3) 0.0042b
ADRs 70 (35.7) 125 (64.4) <0.0001b
Serious AEs 1 (0.5) 1 (0.5) 1.000
Serious ADRs 0 (0.0) 1 (0.5) 0.4974
Discontinuations
due to AEs
15 (7.7) 14 (7.2) 1.000
Discontinuations
due to ADRs
10 (5.1) 14 (7.2) 0.4077
AEs by preferred
term
Somnolence 21 (10.7) 51 (26.3) <0.0001b
Nausea 9 (4.6) 42 (21.6) <0.0001b
Constipation 8 (4.1) 29 (14.9) 0.0002b
Nasopharyngitis 29 (14.8) 26 (13.4) 0.7715
Dry mouth 7 (3.6) 14 (7.2) 0.1218
Decreased
appetite
1 (0.5) 13 (6.7) 0.0008b
Dizziness 2 (1.0) 11 (5.7) 0.0112b
Headache 6 (3.1) 9 (4.6) 0.4437
Fatigue 6 (3.1) 9 (4.6) 0.4437
Diarrhea 7 (3.6) 8 (4.1) 0.7990
ADR adverse drug reaction, AE adverse event
Values are n (%)
aFisher’s exact test
bStatistically significant at a two-sided level of 0.05analysis using LOCF ANCOVA was performed to exa-
mine the potential effects of the degree of depressive
symptoms (divided into a minimal depression group
with baseline BDI-II scores of 0–13 points and a group
with scores ≥14 points according to the BDI-II manual
[35]) and the presence or absence of complications of
major depressive disorder on the improvement of pain.
The between-groups difference in the change in the
BPI average pain score tended to be greater in patients
with a baseline BDI-II score <14 (between-groups dif-
ference, −0.51; 95 % CI, −1.03, 0.02; p = 0.0586) than in
patients with a baseline BDI-II score of ≥14 (between-
groups difference, −0.27; 95 % CI, −0.78, 0.24; p = 0.2946).
In patients without major depressive disorder, the reduction
in the BPI average pain score was significantly greater in
the duloxetine group (between-groups difference, −0.38;
95 % CI, −0.75, 0.00; p = 0.0494). Therefore, treatment with
duloxetine could be associated with an improvement in pa-
tients with very mild depressive symptoms as well as in
those without major depressive disorder.
Changes in associated symptoms of fibromyalgia
Fibromyalgia is characterized by widespread body pain
as well as a variety of symptoms that affect overall health
status and QoL. Therefore, PGI-I and CGI-I scores were
assessed for comprehensive evaluation of illness im-
provement from baseline to 14 weeks of treatment. The
SF-36 and FIQ were used, in addition to the BPI pain
interference scale, to assess the overall impact of fibro-
myalgia on health status. Because fibromyalgia is asso-
ciated with neuropsychiatric symptoms, the BDI-II was
used to assess improvement in these symptoms. In this
study, illness improvement (PGI-I and CGI-I scores) was
significantly higher in the duloxetine group than in the
placebo group. The BPI interference scores for mood, rela-
tionships with people, and enjoyment of life, as well as the
average score for all seven items, were significantly improved
in the duloxetine group compared with the placebo group.
These improvements in the BPI interference scores are simi-
lar to the results of a study conducted in Japanese patients
with diabetic peripheral neuropathic pain [24] who presented
improvements in the scores for walking ability, relationships
with people, sleep, and enjoyment of life items and improve-
ment of −0.48 in the average score of the seven BPI interfer-
ence items. In our study, compared with the placebo group,
the duloxetine group showed significant improvements in
seven subscales of the FIQ (motor dysfunction, emotional
well-being, number of days absent from work or housework,
pain, fatigue, anxiety, and depressive state) and in all eight
subscales of the SF-36, indicating that duloxetine treatment
could be associated with improvement in QoL in this cohort
of patients. We also observed a significant improvement in
the BDI-II score, which indicates that duloxetine improved
psychiatric symptoms in our patient cohort.
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could be associated with a reduction in the pain associated
with fibromyalgia and the improvement of related symp-
toms. Because of the wide array of clinical manifestations
of fibromyalgia, the disease can considerably deteriorate
the QoL of patients. On the basis of the present findings,
duloxetine could potentially improve the QoL of patients
as well as ameliorate depressive symptoms by improving
the symptoms associated with fibromyalgia.
American College of Rheumatology 2010 criteria
Compared with the placebo group, the duloxetine group
showed a significant improvement in WPI and a trend
toward a numerical improvement in SS, indicating an
improvement of clinical symptoms. This result is con-
sistent with the significant improvement in associated
symptoms of fibromyalgia and in several items of the
QoL assessment in patients who received duloxetine in
this study. Moreover, 85.0 % of patients in this study
matched the ACR 2010 criteria for fibromyalgia, which
is consistent with the findings reported by Usui et al.
[37]. The above findings suggest the usefulness of ACR
2010 in the diagnosis of fibromyalgia and the severity as-
sessment of clinical symptoms in clinical studies of
fibromyalgia. Because only a very limited number of
studies evaluating the SS and WPI have been reported to
date, more data are needed to confirm the significance
of the results obtained in the present study.
Onset of effect by once-daily dosing
Generally, patient compliance has been found to in-
crease as dosing frequency decreases [39]. Currently, the
only drug indicated for the treatment of fibromyalgia in
Japan is recommended in a twice-daily administration
regimen. However, on the basis of the results of this and
previous studies, once-daily dosing of duloxetine appears
to be sufficient to improve pain and may improve QoL
outcomes, which may contribute to greater patient com-
pliance and convenience.
Safety
The results of the present short-term study indicate that
there were no significant safety concerns related to
duloxetine treatment. Somnolence, nausea, constipation,
decreased appetite, and dizziness were significantly more
frequent in the duloxetine group than in the placebo
group, which is consistent with previously reported AEs
among patients with approved indications, such as major
depressive disorder [23] and diabetic peripheral neuro-
pathic pain [24]. In addition, comprehensive safety ana-
lysis of studies done in other countries also revealed that
the most common AEs seen during duloxetine treatment
were similar to those observed during treatment with
duloxetine for other indications. Most AEs were mild tomoderate in severity and were transient [19]. Therefore,
in the present study, there were no new findings that
would change the existing duloxetine safety profile. It
will be important to confirm the long-term safety of
duloxetine because patients with chronic pain, such as
those with fibromyalgia, generally undergo long-term
treatment. We have implemented an open-label, long-
term extension trial of this study to continue evaluating
the safety of duloxetine.
Limitations
Some limitations of this study should be mentioned: we
excluded patients with psychiatric disorders other than
depression, and we did not assess the long-term efficacy
and safety of duloxetine.
Conclusions
Although the MMRM analysis did not demonstrate super-
iority of duloxetine over placebo, duloxetine treatment
was associated with improved outcomes in secondary and
post hoc analyses of the mean change of the BPI average
pain score and most of the secondary outcomes, including
analgesia and QoL. No significant safety concerns were
reported during the duloxetine treatment. These results
suggest that treatment with duloxetine could be associated
with improvement in pain relief and QoL in Japanese
patients with fibromyalgia.
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